Venetoclax and azacitidine versus CAG for unfit patients with newly diagnosed acute myeloid leukemia: A propensity score-matched analysis

Key Points

• Venetoclax and azacitidine improved outcomes in patients with acute myeloid leukemia.
• A significant survival advantage was observed over CAG treatment for 12 months.
• Propensity score-matched analysis utilizes a robust statistical method to minimize bias.
• This analysis suggests a potential shift in treatment strategies for unfit patients.